Traders Purchase High Volume of Call Options on Amicus Therapeutics (FOLD)

Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw some unusual options trading on Monday. Investors acquired 47,875 call options on the stock. This represents an increase of 1,767% compared to the average volume of 2,564 call options.

Shares of Amicus Therapeutics (NASDAQ FOLD) opened at $15.17 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics has a 1-year low of $5.87 and a 1-year high of $17.40.

In other Amicus Therapeutics news, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $13.51, for a total value of $885,999.31. Following the transaction, the chief executive officer now directly owns 393,076 shares in the company, valued at approximately $5,310,456.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the transaction, the insider now owns 69,184 shares in the company, valued at $940,210.56. The disclosure for this sale can be found here. Insiders sold a total of 250,390 shares of company stock worth $3,620,581 over the last quarter. Company insiders own 3.40% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC lifted its holdings in shares of Amicus Therapeutics by 3.4% in the 3rd quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock valued at $269,760,000 after buying an additional 591,925 shares during the period. BlackRock Inc. lifted its holdings in shares of Amicus Therapeutics by 2.6% in the 4th quarter. BlackRock Inc. now owns 13,712,097 shares of the biopharmaceutical company’s stock valued at $197,317,000 after buying an additional 342,861 shares during the period. Jennison Associates LLC lifted its holdings in shares of Amicus Therapeutics by 9.4% in the 3rd quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after buying an additional 838,267 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Amicus Therapeutics by 5.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after buying an additional 430,486 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in shares of Amicus Therapeutics by 5.8% in the 3rd quarter. Janus Henderson Group PLC now owns 7,434,314 shares of the biopharmaceutical company’s stock valued at $112,109,000 after buying an additional 407,304 shares during the period.

Several research analysts have weighed in on FOLD shares. BidaskClub downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Zacks Investment Research downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. Cowen reiterated a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Robert W. Baird set a $20.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 7th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $19.06.

WARNING: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/20/traders-purchase-high-volume-of-call-options-on-amicus-therapeutics-fold.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply